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Usinginvitro brainslices of hippocampus and cortex,neuronal oscillations inthefrequency rangeof 30–80Hz(gammafrequency
oscillations)canbeinducedbyanumberofpharmacologicalmanipulations.Themostroutinelyusedisthebathapplicationofthe
broad-spectrum glutamate receptor agonist, kainic acid. In the hippocampus, work using transgenic kainate receptor knockout
mice have revealed information about the speciﬁc subunit composition of the kainate receptor implicated in the generation and
maintenance of the gamma frequency oscillation. However, there is a paucity of such detail regarding gamma frequency oscillation
in the cortex. Using speciﬁc pharmacological agonists and antagonists for the kainate receptor, we have set out to examine
the contribution of kainate receptor subtypes to gamma frequency oscillation in the entorhinal cortex. The ﬁndings presented
demonstrate that in contrast to the hippocampus, kainate receptors containing the GLUK5 subunit are critically important for the
generationandmaintenanceofgammafrequencyoscillationintheentorhinalcortex.Futureworkwillconcentrateondetermining
the exact nature of the cellular expression of kainate receptors in the entorhinal cortex.
Copyright © 2008 Heather L. Stanger et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
KARs are made up of various combinations of ﬁve subunits:
GLUK5,G L U K6,G L U K7,K A 1 ,a n dK A 2[ 1, 2] which are
abundantly expressed in the neocortex [3]. These subunits
make up tetramers of either homomeric or heteromeric
assemblies, with GLUK5–7 being able to form functional
homomericreceptors[1,4].KA1andKA2cannotformfunc-
tional receptors when expressed alone [5, 6], yet are able to
form functional KARs when expressed heteromerically with
other subunits [1, 7, 8]. Diﬀerential patterns of expression of
KARsintheCNScoupledwiththeexistenceofsplicevariants
and mRNA editing suggest complex neurophysiological roles
for the various subunits, and diﬀerent roles in neuronal
networks depending on their localization [9, 10].
OfparticularinterestistheroleofKARsinthegeneration
and maintenance of network neuronal oscillatory activity
in cortical regions [9, 10]. Gamma frequency oscillations
occur between 30–80Hz and have been observed in many
areas of the brain, including the hippocampus [11–13]
and cortical regions [14–16]. Cortical gamma oscillations
are important in higher brain functions, such as learning,
memory, and cognition [17–19], as well as processing of
sensorimotor information [15, 16, 20]. In carrying out these
functions, cortical gamma oscillations are implicated in
various central processes, including long-term potentiation
(LTP) and synaptic plasticity [21], with important roles in
temporal regulation of neuronal activity.
Gamma frequency oscillations are recordable from the
MEC during wakefulness in humans [22, 23], as well as
in vivo in rodents [12], in vitro from perfused guinea
pig brains [24, 25], and isolated rat brain slices [26, 27].
These gamma oscillations in the MEC play a role in the
formation, processing, storage, and retrieval of memories
[17, 18]. Previously it has been demonstrated in an in
vitro preparation of the MEC that application of nanomolar2 Neural Plasticity
concentrations of kainate (200–400nM) can induce per-
sistent gamma frequency oscillations [26–28]. Using this
in vitro model of MEC gamma frequency oscillations it
has been elucidated that this activity is primarily generated
by inhibitory-based neuronal networks [29–31]. A similar
mechanism for the generation of gamma frequency activity
has been demonstrated in both the hippocampus and
neocortex [32, 33].
To date our understanding of the role of the KARs
in neuronal network activity has been hampered by a
paucity of selective pharmacological agents. The com-
petitive AMPA/KAR antagonist, 2,3-dihydroxy-6-nitro-7-
sulfamoyl-benzo[f]quinoxaline (NBQX), shows little selec-
tivity between AMPA receptors and KARs at high concen-
trations, yet at low concentrations (1μM) can be used to
block AMPA receptors, and isolate KAR responses [34, 35].
However, NBQX shows no selectivity between diﬀerent KAR
subunits.TheroleofGL U K5 andGLUK6 subunitsinneuronal
oscillatory activity in the hippocampus has been previously
investigated using receptor knockout mice [9, 10]. However,
interpretation of work using transgenic models should be
viewed in the light of the knowledge that compensatory
factors may play a role. The recent development of pharma-
cological agents with speciﬁcity for distinct subunits has led
to the possibility of a detailed pharmacological investigation
of the role of speciﬁc KARs in cortical gamma frequency
oscillations. (S)-3-(2-Carboxybenzyl)willardiine (UBP302)
is a novel selective GLUK5-containing KAR antagonist,
with activity at both homomeric and heteromeric GLUK5-
containing receptors [36, 37]. The activity of UBP302 on
GLUK7 is controversial, Dolman et al. [37] showed that
UBP296 (racemic form of UBP302) only weakly inhib-
ited [3H]kainate binding to human GLUK7 (Ki value of
374 ± 122μM). However, in an electrophysiological assay
UBP302 was found to block rat homomeric GLUK7 recep-
tors with an IC50 value of 4μM but at a concentration
of 100μM only very weakly blocked rat GLUK6/GLUK7
receptors [38]. 5-Carboxy-2,4-di-benzamido-benzoic acid
(NS3763) is another novel glutamate antagonist, which
is selective and noncompetitive for homomeric GLUK5-
containing KARs [39, 40]. (RS)-2-amino-3-(3-hydroxy-5-
tert-butyl-isoxazol-4-yl)propanoic acid (ATPA) is a selective
GLUK5-containing receptor agonist [41]. ATPA has been
shown to depress excitatory and GABAergic synaptic trans-
mission in the hippocampus [42, 43]. However, Cossart et al.
[35] demonstrated that lower concentrations of ATPA could
directly depolarise hippocampal GABAergic interneurons
leading to increases in the levels of tonic inhibition onto
pyramidal neurons. More recently, similar concentrations
of ATPA to that used in the Cossart et al. [35]s t u d y
have been shown to facilitate both evoked and action
potential-independent glutamate release in the neocortex
[44].
The data presented here demonstrates a role of GLUK5-
containing KARs in the MEC by examining the contri-
bution of these receptor subtypes to gamma frequency
oscillations. Using a pharmacological approach, we have
demonstrated that GLUK5-containing KARs are important
for the maintenance of gamma frequency oscillations in
the MEC. Moreover, the selective activation of GLUK5-
containing KARs can induce persistent gamma frequency
oscillations in the MEC. We also demonstrate that it is the
speciﬁc activation of homomeric GLUK5-containing KARs
that is important for the generation of gamma frequency
oscillations in the MEC.
2. MATERIAL AND METHODS
2.1. PreparationofEC-hippocampalslices
All procedures involving animals were carried out in accor-
dance with UK Home Oﬃce Legislation. Male Wistar rats,
weighing >150grammes, were ﬁrst anaesthetised by inhala-
tion of the volatile anaesthetic isoﬂuorane. This was imme-
diately followed by intramuscular injection of a terminal
dose of ≥100mg/kg ketamine and ≥10mg/kg xylazine. After
conﬁrmation of deep anaesthesia, rats were intracardiacally
perfused with ∼50mL sucrose-modiﬁed artiﬁcial cerebral
spinal ﬂuid (aCSF), composed of (in millimolar (mM)): 252
sucrose,3K Cl,1.25N aH 2PO4,2M g S O 4,2C a C l 2·2H2O, 10
glucose, and 24 NaHCO3. All salts were obtained from BDH
Laboratory Supplies (Poole, UK), except MgSO4 which was
obtained from Sigma Chemical Co (Mo, USA).
The whole brain was rapidly removed and maintained
in a bath of cold sucrose-modiﬁed aCSF (4-5◦C) during
the dissection procedure. Horizontal slices (450μm thick)
were cut using a vibroslice (Leica VT1000S). Transverse
EC-hippocampal slices were then transferred either to a
holding chamber or directly to the recording chamber. They
were maintained at 32 ± 1◦C, at the interface between a
continuous perfusion (∼2-3mL/min) of NaCl-based aCSF
(containing (in mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4,
1M g S O 4,1 . 2C a C l 2·2H2O, 10 glucose, 24 NaHCO3)a n d
humidiﬁed carbogen gas (95% O2/5% CO2). Slices were
allowed to equilibrate for 60 minutes before any recordings
were taken.
2.2. Electrophysiologicalrecordingand
drugapplication
Extracellular recordings were taken using glass electrodes
pulled from borosilicate glass capillaries (GC129 TF-10,
1.2mm OD/0.94mm ID) (Harvard Apparatus, Kent, UK)
using a Flaming/Brown micropipette puller, model P-97
(Sutter Instrument Co., Calif, USA). This created electrodes
withresistancesof2–4MΩ.ElectrodeswereﬁlledwithNaCl-
based aCSF and positioned in Layer III of the MEC. Control
readings were taken from slices before drug application to
conﬁrm that any network activity seen following treatment
was due to the presence of drugs.
To evoke gamma frequency oscillations, 400nM
kainic acid ((2S,3S,4S)-3-carboxymethyl-4-(prop-1-en-2-yl)
pyrrolidine-2-carboxylic acid; Tocris Cookson, Bristol,
UK) was bath applied to EC-hippocampal slices and left
to equilibrate for 2-3 hours or until gamma oscillations
had stabilised. All other drugs were bath applied to slicesHeather L. Stanger et al. 3
at known concentrations: UBP302 ((S)-3-(2-carboxyben-
zyl)willardiine; gift from Dr. David Jane, Department
of Pharmacology, University of Bristol, UK) at 10μM;
ATPA ((RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-
yl)propanoic acid; Tocris Cookson, Bristol, UK) at 1–5μM;
NS3763 (5-carboxy-2,4-di-benzamido-benzoic acid; Tocris,
Bristol, UK) at 10–15μM; NBQX (2,3-dihydroxy-6-nitro-
7-sulfamoyl-benzo[f]quinoxaline; Tocris, Bristol, UK) at
1–10μM; and Carbachol (Sigma, UK) at 10–20μM.
2.3. Dataacquisition
An AppleMac computer with the Axograph OSX software
package(AxographX,Dr.JohnClements,Australia)wasused
foralldataacquisition.Signalswereanalogueﬁlteredat0.01–
0.3kHz and then digitized at a frequency of 10kHz. Power
spectra were constructed, where power at a given gamma
frequency was deﬁned as the area under the peak between
20 and 80Hz. Power spectra were generated from digitized
data, using 60second epochs of recorded activity, and it was
from these spectra that values for gamma oscillation peak
frequency, peak amplitude, and spectral area power in the
gamma frequency band were obtained.
2.4. Dataanalysis
Data analysis was carried out using Excel and Kaleidagraph
software packages. Kaleidagraph software was used to gener-
ate pooled power spectra, and the Excel package was used
to calculate the mean and standard error of mean (SEM)
of results, and to draw up histograms and line graphs. All
dataispresentedasmean ±SEM.SigmaStat(Systatsoftware,
USA) was used for all statistical tests. Normality tests were
carriedout,andifdatawasfoundtobenormallydistributed,
two-tailed paired t-tests were run. However, if data failed the
normality test, the Wilcoxon signed rank test was carried
out. This provided us with P-values for all data sets, and the
signiﬁcance level was set at 95%; values less thanP = .05 were
deemed to be statistically signiﬁcant.
3. RESULTS
3.1. Inductionofkainate-driven
gammaoscillationsintheMEC
Previously, it has been demonstrated that low concentrations
of kainic acid (kainate) evoke gamma frequency activity
in the rat MEC in vitro [26, 27]. In this investigation, we
produced persistent gamma oscillations in the MEC by bath
application of kainate (400nM) (Figure 1). Robust gamma
frequency oscillations (39.4 ± 1.6Hz; n = 17) were evoked
in layer III of the MEC in all slices to which kainate had
been applied (n = 17). This activity was generated within
15 minutes of kainate superfusion, a stable baseline was
observed after 60–90 minutes. As previously reported [19],
applicationofthecompetitiveAMPA/KARantagonistNBQX
(10μM) eﬀectively abolished these kainate-induced gamma
oscillations (n = 3) (Figure 1).
Control
+ kainate (400nM)
+N B Q X( 1 0μM)
i
ii
iii
Figure 1: Gamma frequency oscillations can be induced in layer
III of the MEC by application of kainate. (a) Extracellular ﬁeld
recordingsshowing1secondepochsofactivity(i)incontrolsetting,
(ii) following application of 400nM kainate, and (iii) following
applicationof10μMNBQXinthepresenceof400nMkainate.Scale
bar represents 200 milliseconds and 100μV.
3.2. AroleforGLUK5-containingKARsin
themaintenanceofkainate-driven
gammaoscillations
Ap o s s i b l er o l ef o rG L U K5-containing KARs in the main-
tenance of kainate-driven gamma frequency oscillations in
the MEC was investigated by testing the ability of the
GLUK5 selective antagonist, UBP302, to inhibit preestab-
lished kainate-induced gamma activity. Gamma oscillations
were generated in the MEC by bath application of kainate
(400nM) and allowed to stabilise (n = 9) (Figure 2(a)). In
the presence of UBP302 (10μM), the amplitude of kainate-
induced gamma oscillations was signiﬁcantly reduced (con-
trol, 116.7 ± 44.1μV2/Hz; v. UBP302, 70.0 ± 30.3μV2/Hz;
P < .05; n = 9), and area power of oscillations was also
signiﬁcantlydecreased(control,1586.0±503.3μV2/Hz.Hz;v.
UBP302, 1155.1 ± 441.4μV2/Hz.Hz; P < .05; n = 9) (Figures
2(a), 2(b)). However, following UBP302 application, the
frequency of oscillations remained unchanged (control,
40.4 ± 2.1Hz; v. UBP302, 38.9 ± 2.6Hz; P > .1; n = 9).
Washout of the eﬀects of UBP302 on gamma frequency
oscillationscouldnotbeachieved(n=9)(Figures2(a),2(b)).
3.3. AroleforGLUK5-containingKARsinthe
generationofgammaoscillationsintheMEC
To investigate the role that GLUK5-containing KARs may
play in the induction of kainate-driven gamma oscillations,4 Neural Plasticity
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Figure 2: Antagonizing GLUK5-containing KARs with UBP302 inhibits kainate-driven gamma frequency oscillations in the MEC. (a)
Extracellular ﬁeld recordings showing 1 second epochs of activity (i) in the presence of 400nM kainate, (ii) following 10μM UBP302
application, and (iii) during a washout period into 400nM kainate. (b) Pooled power spectra (n = 9) produced from 60 second epochs
of extracellular ﬁeld recorded data, showing a control recording (black), a recording in the presence of 400nM kainate (blue), application of
10μM UBP302 (green), and washout back into 400nM kainate (red). Scale bar represents 200 milliseconds and 100μV.
we carried out two experiments, using the selective GLUK5-
containing KAR agonist, ATPA, and antagonist, UBP302.
First, we tested the ability of UBP302 to inhibit the
generation of a kainate-driven gamma frequency oscillation
in the MEC. Slices were preincubated in UBP302 (10μM)
for 30 minutes. As expected, UBP302 administration caused
no neuronal network activity in slices (n = 11) (Figure 3(a)).
However, when kainate was applied to slices following prein-
cubation with UBP302, gamma frequency oscillations were
generated in all slices (n = 11) (Figure 3(a)). On washout
into kainate alone (400nM), although the frequency of
oscillations did not change signiﬁcantly (in presence of
kainate following preincubation with UBP302, 45.4±2.0Hz;
v. 400nM kainate alone, 40.3 ± 0.9Hz; P > .05; n = 11),
oscillations were seen to increase signiﬁcantly in both peak
amplitude (in presence of kainate following preincubation
with UBP302, 39.2 ± 12.1μV2/Hz; v. 400nM kainate alone,
122.9 ± 32.8μV2/Hz; P < .05; n = 11) and area power (in
presence of kainate following preincubation with UBP302,
545.1 ± 159.6μV2/Hz.Hz; v. 400nM kainate alone, 1302.5 ±
241.4μV2/Hz.Hz; P < .05; n = 11) (Figures 3(a), 3(b)).
We next investigated whether gamma frequency oscil-
lations could be generated in the MEC by application of
the GLUK5 selective agonist, ATPA. ATPA was bath applied
to slices at concentrations of 1μM, 2μM, and 5μM. ATPA
induced gamma frequency oscillations in the MEC in theHeather L. Stanger et al. 5
Preincubation UBP302 (10μM)
+ kainate (400nM)
Washout (kainate 400nM)
i
ii
iii
(a)
0
6
12
1 10 100 1000
Frequency (Hz)
P
o
w
e
r
(
1
0
−
1
1
μ
V
2
/
H
z
)
Control
+10μM UBP302
+400nM kainate
Kainate washout
(b)
Figure 3: Preincubation of slices in UBP302 inhibits the ability of the MEC network to produce kainate-driven gamma frequency
oscillations. (a) Extracellular ﬁeld recordings showing 1 second epochs of activity (i) following preincubation with 10μM UBP302, (ii)
following application of 400nM kainate onto preincubated slices, and (iii) during a washout period into 400nM kainate. (b) Pooled power
spectra (n = 11) produced from 60 second epochs of extracellular ﬁeld recorded data, showing a control recording (black), a recording
following 10μM UBP302 preincubation (blue), 400nM kainate application following preincubation (green), and washout into 400nM
kainate (red). Scale bar represents 200 milliseconds and 100μV.
majority of slices to which the agonist was applied (n = 18
out of a total n = 26) (Figure 4(a)). Slices showing gamma
oscillations upon ATPA application were observed to be
dorsal MEC slices. Upon increasing the concentration of
ATPA in slices demonstrating gamma oscillations, the mean
frequency, peak amplitude, and area power of oscillations
increased (n = 10) (Figures 4(a), 4(b)). The frequency
of oscillations increased from 23.0 ± 1.9Hz, to 34.0 ±
2.4Hz, and to 44.2 ± 1.5Hz (n = 10) (Figure 4(b)), the
peak amplitude increased from 0.9 ± 0.5μV2/Hz, to 4.1 ±
2.3μV2/Hz, and to 23.3 ± 8.7μV2/Hz (n = 10) (Figure 4(b)),
and the power increased from 23.1 ± 12.6μV2/Hz.Hz, to
88.4 ± 38.9μV2/Hz.Hz, and to 201.8 ± 71.0μV2/Hz.Hz, at
the respective concentrations of ATPA (1μM, 2μM, and
5μM) (n = 10) (Figure 4(b)). Control readings, taken before
ATPA administration, showed that no network activity was
spontaneouslypresentinslices(n=26)(Figure 4(a)i).ATPA-
induced gamma frequency oscillations were susceptible to
the AMPA/KAR antagonist NBQX (10μM) (n = 3).
We next investigated the eﬀect of UBP302 on ATPA-
induced gamma frequency oscillations in the MEC. Gamma
frequency oscillations were induced in slices by bath appli-
cation of ATPA (2–5μM) (n = 4) (Figure 5(a)i). UBP302
(10μM) application caused no signiﬁcant change in the
frequency of gamma oscillations (control, 42.7 ± 3.9Hz;
v. UBP302, 33.9 ± 7.3Hz; P > .1; n = 4) and yet had
signiﬁcant eﬀects on both the peak amplitude (control,
20.8±7.1μV2/Hz;v. UBP302,6.6±2.8μV2/Hz;P <.05;n=4)
and power of oscillations (control, 359.7±117.9μV2/Hz.Hz;
v. UBP302, 141.7 ± 61.9μV2/Hz.Hz; P < .05; n = 4)
(Figures 5(a)ii, 5(b)). The eﬀects of UBP302 on an ATPA-
inducedgammafrequencyoscillationswerenotreversibleon
washout (n = 4).
3.4. AroleforhomomericGLUK5-containingKARsin
gammafrequencyoscillations
The GLUK5 selective KAR antagonist, NS3763, was used
to investigate the contribution of homomeric GLUK5-
containing KARs to gamma activity in the MEC. NS3763
selectively antagonises homomeric GLUK5 KARs [39]a n d
experiments were carried out to determine the role of these
homomeric receptors in both kainate- and ATPA-induced
gamma oscillations.
Application of NS3763 (10–15μM) caused signiﬁ-
cant decreases in both peak amplitude (control, 100.2 ±
48.4μV2/Hz; v. NS3763, 46.0 ± 23.7μV2/Hz; P < .05; n =
8) and area power (control, 822.9 ± 273.2μV2/Hz.Hz; v.
NS3763, 449.4±182.3μV2/Hz.Hz; P < .05; n = 8) of kainate-
induced gamma oscillations in the MEC (Figures 6(a), 6(b)).
However, no eﬀect was seen on the frequency of kainate-
generated oscillations (control, 38.3 ± 2.7 Hz; v. NS3763,
36.0 ± 1.5Hz; P > .1; n = 8) (Figure 6(b)).
Application of NS3763 (10–15μM) to slices demon-
strating ATPA-induced gamma oscillations caused no sig-
niﬁcant change in the frequency of oscillations (control,6 Neural Plasticity
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Figure 4: Activation of GLUK5-containing KARs can induce gamma frequency oscillations in the MEC. (a) Extracellular ﬁeld recordings
showing 1 second epochs of activity in a control setting (i) following application of 1μM, (ii) 2μM (iii), and 5μM ATPA (iv). (b) Pooled
line graphs (n = 10) demonstrating the eﬀects of varying ATPA concentration on (i) frequency, (ii) area power, and (iii) peak amplitude of
gamma oscillations in the MEC. Scale bar represents 200 milliseconds and 100μV.
46.7 ±3.8Hz; v. NS3763, 38.5 ± 6.2Hz; P > .1; n = 8)
(Figures7(a),7(b)).However,thepresenceofNS3763caused
a signiﬁcant decrease in both the peak amplitude (control,
191.9±63.1μV2/Hz; v. NS3763, 28.5±13.6μV2/Hz; P < .05;
n = 8) and area power (control, 1192.9 ± 342.8μV2/Hz.Hz;
v. NS3763, 333.6 ± 120.5μV2/Hz.Hz; P < .05; n = 8)
of gamma oscillations (Figures 7(a), 7(b)). The eﬀects
of NS3763 on either kainate- or ATPA-induced gammaHeather L. Stanger et al. 7
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Figure 5: ATPA-generated gamma frequency oscillations in the MEC are reduced by application of the GLUK5 selective antagonist, UBP302.
(a)Extracellularﬁeldrecordingsshowing1secondepochsofactivity(i)inthepresenceof5μMATPAand(ii)followingapplicationof10μM
UBP302. (b) Pooled power spectra (n = 4) produced from 60 second epochs of extracellular ﬁeld recorded data, showing a control recording
(black), recording in the presence of 5μM ATPA (blue), and application of 10μM UBP302 (green). Scale bar represents 200 milliseconds and
100μV.
frequency oscillations were not reversible on washout (n =
12).
3.5. AroleforGLUK5-containingKARsin
carbachol-inducedgammaoscillations
Cortical gamma frequency oscillations can also be induced
by application of carbachol, an agonist at muscarinic acetyl-
choline receptors (mAChRs) [24, 25, 45–49]. It is unclear
as to the role of GLUK5-containing KARs in a cholinergic-
mediated gamma frequency oscillation in the MEC. Carba-
chol will cause an increase in the release of glutamate in
the form of rhythmic EPSPs [46]. This, in turn, may lead to
activation of KARs [50]. In agreement with previous studies
in the MEC [24, 25] bath application of carbachol (10–
20μM)generatedpersistentgammafrequencyoscillations(n
= 6) (Figure 8(a)i). Application of UBP302 (10μM) had no
signiﬁcant eﬀect on the frequency (control, 41.7 ± 1.6 Hz;
v. UBP302, 40.3 ± 0.6Hz; P > .1; n = 6), peak amplitude
(control, 5.9 ± 3.1μV2/Hz; v. UBP302, 5.5 ± 2.5μV2/Hz; P
> .1; n = 6) or power (control, 155.2 ± 72.7μV2/Hz.Hz;
v. UBP302, 148.7 ± 62.8μV2/Hz.Hz; P > .1; n = 6) of
preestablished carbachol-driven gamma oscillations (Figures
8(a)ii, 8(b)). This lack of eﬀect was further demonstrated by
washout back into carbachol causing no signiﬁcant change
in observed gamma frequency oscillations (Figures 8(a)iii,
8(b)).
4. DISCUSSION
A number of studies have examined the contribution of
various KAR subunits to gamma frequency oscillations
in the hippocampus in vitro. Fisahn et al. [10]f o c u s e d
on the roles of GLUK5 and GLUK6 subunits in kainate-
induced hippocampal gamma oscillations, using brain slices
from transgenic GLUK5 and GLUK6 receptor knockout
mice. Knockout of GLUK5 caused increased sensitivity of
the hippocampal network to the eﬀects of kainate and
higher susceptibility to oscillatory and epileptogenic activ-
ity. Slices from GLUK6-knockout mice could not support
kainate-induced gamma oscillations or epileptiform activity,
suggesting distinct roles for GLUK5 and GLUK6 subunits
in the hippocampus. Fisahn et al. [10] concluded that
GLUK5-containing receptors may be expressed on axons of
hippocampal interneurons and have a function in inhibitory
tone, and that GLUK6-containing KARs may be found in the
somatodendritic region of pyramidal cells and interneurons,
and provide excitatory drive. Functional receptors of both
subtypes must interact to allow generation of stable gamma
oscillations in the hippocampus [9, 10].
Subsequently, Brown et al. [51] used pharmacological
approaches to investigate the role of GLUK5-containing
receptors in hippocampal gamma oscillations. This study
used the GLUK5-selective agonists ATPA and iodowillardiine
but found that neither could induce gamma network activity
in area CA3 of rat hippocampal slices. The GLUK5 selective8 Neural Plasticity
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Figure 6: Blocking homomeric GLUK5-containing KARs signiﬁcantly reduces kainate-driven gamma frequency oscillations in the MEC.
(a) Extracellular ﬁeld recordings showing 1 second epochs of activity (i) in the presence of 400nM kainate and (ii) following application of
10μM NS3763. (b) Pooled power spectra (n = 8) produced from 60 second epochs of extracellular ﬁeld recorded data, showing a control
recording(black),recordinginthepresenceof400nMkainate(blue),applicationof10μMNS3763(green),andawashoutbackinto400nM
kainate (red). Scale bar represents 200 milliseconds and 100μV.
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Figure 7: Blocking homomeric GLUK5-containing KARs eﬀectively reduces power and amplitude of ATPA-generated gamma frequency
oscillations in the MEC (a) Extracellular ﬁeld recordings showing 1 second epochs of activity (i) in the presence of 5μM ATPA and (ii)
following application of 15μM NS3763. (b) Pooled power spectra (n = 4) produced from 60 second epochs of extracellular ﬁeld recorded
data, showing a control recording (black), recording in the presence of 5μMA T P A( b l u e ) ,a n da p p l i c a t i o no f1 5μM NS3763 (green). Scale
bar represents 200 milliseconds and 100μV.Heather L. Stanger et al. 9
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Figure 8: Carbachol-induced gamma frequency oscillations are not dependent on GLUK5-containing KARs. (a) Extracellular ﬁeld
recordings showing 1 second epochs of activity (i) in the presence of 20μM carbachol, (ii) following 10μM UBP302 application, and (iii)
during a washout period into 20μM carbcahol. (b) Pooled power spectra (n = 6) produced from 60 second epochs of extracellular ﬁeld
recorded data, showing a control recording (black), recording in the presence of 20μM carbachol (blue), application of 10μM UBP302
(green), and washout back into 20μM carbachol (red). Scale bar represents 200 milliseconds and 100μV.
antagonist, UBP296, when preincubated with hippocampal
slices, did not prevent induction of kainate-driven gamma
oscillations. However, UBP296 produced an approximately
50% reduction in the power of preestablished kainate-
induced gamma frequency oscillations. This paper con-
cluded that GLUK5-containing KARs alone cannot generate
gamma oscillations in the hippocampus but may be involved
in maintenance of hippocampal gamma activity generated
through other KAR subtypes.
Inthepresentstudy,wehavedemonstratedthat,similarly
to in the hippocampus [51], GLUK5-containing KARs in
the MEC have a role in the maintenance of kainate-driven
oscillations. UBP302, a GLUK5 selective antagonist, caused
reductionsinpeakamplitudeandspectralpowerofpreestab-
lished kainate-induced gamma frequency oscillations in the
MEC. Furthermore, pretreatment of slices with UBP302
partially inhibited generation of kainate-induced gamma
frequency oscillations, suggesting that GLUK5-containing
KARs are at least partially responsible for the induction
of gamma oscillations by kainate application. These data
suggest that in the MEC, diﬀerently to in the hippocampus
[5, 8, 9], activation of GLUK5-containing KARs plays a
role in the ability of MEC neuronal networks to generate
gamma frequency oscillations. Moreover, in contrast to
hippocampal gamma evoked by kainate, MEC gamma
generated with GLUK5 agonists demonstrates a frequency
increment with increased excitatory drive. This may reﬂect
the manifestation of fundamentally diﬀerent mechanisms
of local circuit gamma oscillation generation in these two
regions.
It was not surprising then that application of the GLUK5
subunit selective agonist ATPA [41] successfully evoked
gamma frequency oscillations in the MEC. However, care
must be taken with interpretation of this data as ATPA has
recently been shown not to be entirely selective for GLUK5-
containingKARs[40].Infact,ATPAcanactivatebothhomo-
meric and heteromeric KAR complexes containing GLUK5,
andalsoGLUK6/KA2heteromericKARs[48].Thus,itcannot
initially be assumed that these gamma oscillations have
been generated via GLUK5-containing receptor complexes,
since they could have been induced through GLUK6/KA2
heteromeric receptors. UBP302, however, is an antagonist
with selectivity for GLUK5-containing KARs [36, 37]. Whilst
UBP302 has been shown to block GLUK7 with an IC50 value
of 4μM—this makes it ∼10-fold selective for GLUK5 versus
GLUK7—it does not have activity on GLUK6 or GLUK6/KA2
up to 100μM. Indeed, some controversy surrounds the
activity of UBP302 on GLUK7 as it has been reported
that UBP302 failed to demonstrate any potent activity in
a binding assay on GLUK7 (personal communication, D.E.
Jane). In any case, as UBP302 only blocks homomeric
GLUK7 andactivationof GLUK7 requires veryhigh glutamate
concentrations (EC50 value 5.9mM) [52]i tm a yn o tb e
relevant to this study. Application of UBP302 onto slices
showing ATPA-generated network activity causes reduced
peak amplitude and an approximately 60% reduction in
area power of gamma frequency oscillations. This inhibition
of ATPA-generated gamma oscillations by UBP302 suggests
that the observed activity must, at least in part, be due to
activation of GLUK5-containing KARs.10 Neural Plasticity
Moreover, NS3763 application caused a signiﬁcant
r e d u c t i o ni np e a ka m p l i t u d ea n ds p e c t r a lp o w e ro fp r e e s t a b -
lished kainate-driven gamma oscillations. This demonstrates
that homomeric GLUK5-containing KARs are at least par-
tially responsible for the maintenance of these kainate-
driven gamma frequency oscillations. Application of NS3763
to preestablished ATPA-generated oscillations caused an
approximately 80% reduction in area power of gamma fre-
quency oscillations and also a reduction in peak amplitude.
This suggests that a large component of an ATPA-driven
gammaoscillationismaintainedthroughhomomericGLUK5
KARs. The activity of the selective homomeric GLUK5-
containing KAR antagonist, NS3763, on both kainate- and
ATPA-generated gamma frequency oscillations, tells us that
homomeric GLUK5-containing KARs are involved in the
observed network activity.
Ithasbeensuggestedthatcarbachol-drivenactivitycould
cause excess glutamate release and that this overspill of
glutamate could activate KARs [50]. The lack of eﬀect
of the GLUK5 selective antagonist, UBP302, on carbachol-
induced gamma oscillations in the MEC suggests that
GLUK5-containing KARs are not involved in the generation
or maintenance of gamma oscillations induced via activation
of muscarinic cholinergic receptor. However, we cannot rule
out the possibility that other KAR subtypes may be involved
in these mAChR-mediated gamma oscillations.
We have shown that GLUK5-containing KARs are impli-
cated in the generation and maintenance of gamma fre-
quency oscillations in the MEC evoked by kainate. How-
ever, we can only speculate on the cellular localisation of
these GLUK5-containing receptors in the MEC. Research
performed by Christensen et al. [40] in the hippocampus,
suggested likely localisations of KAR subtypes in hip-
pocampal CA1 inhibitory interneurons terminating with
pyramidal cells, concluding that heteromeric GLUK6/KA2
receptors are expressed in somatodendritic compartments of
interneurons, and that GLUK5 complexes, with either GLUK6
or KA2, are found at presynaptic terminals. It seems likely
from our results that in the MEC, both homomeric and
heteromeric GLUK5-containing KARs are present.
PresynapticKARsareinvolvedinregulationandmodula-
tion of neurotransmitter release at inhibitory and excitatory
synapses in the hippocampus [50, 53, 54]. In contrast,
postsynaptic KARs mediate excitatory postsynaptic currents
(EPSCs) in many brain regions [35, 55]. KAR activation
in the hippocampus modulates GABA release at terminals
of inhibitory interneurons and causes an increase in spon-
taneous IPSCs but a reduction in the amplitude of these
IPSCs impinging on to CA1 interneurons [40]. This suggests
that KARs may be present in two distinct populations in
hippocampal inhibitory interneurons, and the same may
be true of KARs in the MEC [2, 40]. However, other
reports have demonstrated that kainate can increase the
frequency and amplitude of spontaneous IPSCs, but not
action potential-independent miniature IPSCs in stratum
radiatum interneurons [56]. Moreover, these authors also
observed that kainate can directly depolarise the axonal
plexus of inhibitory interneurons producing both increased
antidromic and presumably orthodromic spiking. This eﬀect
would explain the ability of KAR activation to increase
spontaneous but not miniature IPSC activity. The presence
of KARs at an axonal loci has been well documented in the
hippocampus, most notably in mossy ﬁbres [57, 58].
As outlined in the previous paragraph, there is a large
corpus of data on the role of KAR in the hippocampus.
However, with respect to the MEC there is a paucity of such
information. In order to put the current results presented
in this paper into context, future work will concentrate on
combiningintracellularrecordingsfromindividualneurones
(pyramidal and interneuron), speciﬁc pharmacological KAR
tools, and transgenic KAR subunit knockout animals [9, 10]
to elucidate the exact nature of cellular expression of KARs
in the MEC.
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